Neurocysticercosis-new millennium, ancient disease and unending debate

Indian Journal of Pediatrics

Volumn 70, Issue 4, 2003, Pages 337-342

  Narula, Gaurav ^a,b   Bawa, K S ^a  

^a INHS Asvini ^*  (India)

^b INHS   (India)

Author keywords

Classification; Cysticidal therapy; Neurocysticercosis

Indexed keywords

ALBENDAZOLE; ANTICONVULSIVE AGENT; CARBAMAZEPINE; CIMETIDINE; CORTICOSTEROID; DEXAMETHASONE; NC 3 ANTIGEN; PARASITE ANTIBODY; PARASITE ANTIGEN; PHENOBARBITAL; PHENYTOIN; PLACEBO; PRAZIQUANTEL; PREDNISOLONE; UNCLASSIFIED DRUG; VALPROIC ACID;

ANTIBODY DETECTION; BRAIN; BRAIN CYST; BRAIN RADIOGRAPHY; BRAIN VENTRICLE PERITONEUM SHUNT; CARBOHYDRATE DIET; CEREBROSPINAL FLUID ANALYSIS; CESTODE; CLINICAL FEATURE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CORTICOSTEROID THERAPY; DIAGNOSTIC ERROR; DIAGNOSTIC IMAGING; DIAGNOSTIC PROCEDURE; DISEASE CLASSIFICATION; DISEASE COURSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; ECHOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; EOSINOPHILIA; EYE; FECES ANALYSIS; HEMATOLOGY; HUMAN; HYDROCEPHALUS; INFECTION PREVENTION; INFESTATION; INTERMETHOD COMPARISON; NEUROCYSTICERCOSIS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PARASITE IDENTIFICATION; PARENCHYMA; PATHOGENESIS; PATHOLOGY; PEDIATRICS; REVIEW; SEIZURE; SIDE EFFECT; SINGLE DRUG DOSE; SPINAL CORD; TAENIA SOLIUM; TREATMENT INDICATION;

EID: 0038249119     PISSN: 00195456     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02723590     Document Type: Review

References (41)

1. Faust ER, Russel PF. Taenia Solium-Linnaeus, 1758. In Craig and Faust's Clinical Parasitology, 7th edn. Philadelphia: Lea and Febiger; 1964; 662-669.
2. Bern C, Garcia HH, Evans C, Gonzalez AE, Verastegui M, Tsang VC et al. Magnitude of the disease burden from neurocysticercosis in a developing country. Clin Infect Dis 1999; 29 (5): 1203-1209.
3. Clemov FG. The Geography of Disease. Cambridge University Press; 1903; 569-570.
4. Roberts T, Murrel KD, Marks S. Economic losses caused by food borne parasitic diseases. Parasitology Today 1994; 11: 419-423.
5. White AC Jr, Robinson P, Kuhn R. Taenia Solium cysticercosis: host parasite interactions and the immune response. In Freedman DO, edn. Immunopathogenetic Aspects of Disease Induced by Helminth Parasites. In ser. Chemical Immunology. Basel: Karger; 1997. 66: 209-30.
6. th edn. New York: Mc Graw Hill; 1998; 1224-1227.
7. Hubert K, Andriantsimahavandy A, Michault A, Frosch M, Muhlschlegel FA. Serological diagnosis of human cysticercosis by use of recombinant antigens from Taenia solium cysticerci. Clin Diagn Lab Immunol 1999; 6 (4): 479-482.
8. Garcia HH, Herrera G, Gilman RH, Tsang VC, Pilcher JB, Diaz JF et al. Discrepancies between cerebral computed tomography and western blot in the diagnosis of neurocysticercosis. The Cysticercosis Working Group in Peru (Clinical Studies Coordination Board). Am J Trop Med Hyg 1994; 50 (2): 152-157.
9. Winograd E, Rojas AP. Identification of two nonglycosylated polypeptides of Taenia solium recognized by immunoglobulins from patients with neurocysticercosis. Parasitol Res 1999; 85 (7): 513-517.
10. Dekumyoy P, Vanijanonta S, Waikagul J, Sa-nguankiat S, Danis M. Use of delipidized antigens of Taenia solium metacestodes in IgG-ELISA for detection of neurocysticercosis. Southeast Asian J Trop Med Public Health 1998; 29 (3): 572-578.
11. White AC Jr. Neurocysticercosis: Updates on Epidemiology, Pathogenesis, Diagnosis, and Management. Annu Rev Med 2000; 51: 187-206.
12. Escobar A. The pathology of neurocysticercosis. In Palacios E, Rodriguez- Carbajal J, Taveras J, eds. Cysticercosis of the Central Nervous System. Springfield, IL: Thomas, 1983: 27-54.
13. Cardenas F, Quiroz H, Plancarte A et al. Taenia solium ocular cysticercosis: findings in 30 cases. Ann Ophthalmol 1992; 24: 25-28.
14. Sze G, Lee SH. Infectious Diseases. In Lee SH, Rao KCVG, Zimmerman RA, eds. Cranial MRI and CT. New York: McGraw Hill, 1999; 494-499.
15. Del Brutto OH, Wadia NH, Dumas M et al. Proposal of diagnostic criteria for human cysticercosis and neurocysticercosis. J Neurol Sci 1996; 142: 1-6.
16. Carpio A. Diagnostic criteria for human cysticercosis. J Neurol Sci 1999; 161: 185-188.
17. Kramer LD, Locke GE, Byrd SE. Cerebral cysticercosis: documentation of natural history by CT. Radiology 1989; 171: 459-462.
18. Carpio A, Santillan F, Leon P et al. Is the course of neurocysticercosis modified by treatment with antihelminthic agents? Arch Intern Med 1995; 155: 1982-1988.
19. Mitchell WG, Crawford TO. Intraparenchymal Cerebral Cysticercosis in Children: Diagnosis and Treatment. Pediatrics 1988; 82: 76-82.
20. Padma MV, Behari M, Misra NK, Ahuja GK. Albendazole in neurocysticercosis. Natl Med J India 1995; 8(6): 255-258.
21. Del Brutto OH. Is the course of neurocysticercosis modified by treatment with anthelmintic agents? Arch Intern Med 1997; 157 (1): 128-130.
22. de Silva N, Guyatt H, Bundy D. Anthelmintics. A comparative review of their clinical pharmacology. Drugs 1997; 53 (5): 769- 788.
23. Sotelo J, Jung H. Pharmacokinetic optimisation of the treatment of neurocysticercosis. Clin Pharmacokinet 1998; 34(6): 503-515.
24. Corona T, Lugo R, Medina R, Sotelo J. A short praziquantel regimen for the treatment of parenchymatous neurocysticercosis. Gac Med Mex 1999; 135 (4): 369-72.
25. Del Brutto OH, Campos X, Sanchez J, Mosquera A. Single-day praziquantel versus 1-week albendazole for neurocysticercosis. Neurology 1999; 52 (5): 1079-1781.
26. De Ghetaldi LD, Norman RM, Couville AW. Cerebral cysticercosis treated biphasically with dexamethasone and praziquantel. Ann Intern Med 1983; 99: 179-181.
27. Garcia HH, Gilman RH, Horton J et al. Albendazole therapy for neurocysticercosis: a prospective double-blind trial comparing 7 versus 14 days of treatment. Cysticercosis Working Group in Peru. Neurology 1997; 48(5): 1421-1427.
28. Cruz I, Cruz ME, Carrasco F, Horton J. Neurocysticercosis: optimal dose treatment with albendazole. J Neurol Sci 1995; 133 (1-2): 152-154.
29. Salinas R, Counsell C, Prasad K, Gelband H, Garner P. Treating neurocysticercosis medically: a systematic review of randomized, controlled trials. Trop Med Int Health 1999; 4 (11): 713-718.
30. Apuzzo MLJ, Dobkins WR, Zee CS et al. Surgical considerations in treatment of intraventricular cysticercosis. J Neurosurg 1984; 60: 400-407.
31. Cudlip SA, Wilkins PR, Marsh HT. Endoscopic removal of a third ventricular cysticercal cyst. Br J Neurosurg 1998; 12 (5): 452-454.
32. Bergsneider M, Holly LT, Lee JH, King WA, Frazee JG. Endoscopic management of cysticercal cysts within the lateral and third ventricles. J Neurosurg 2000; 92 (1): 14-23.
33. Sotelo J. Treatment of brain cysticercosis. Surg Neurol 1997; 48: 110-112.
34. Couldwell WT, Zee CS, Apuzzo MN. Definition of the role of contemporary surgical management in cisternal and parenchymatous cysticercosis cerebri. Neurosurgery 1991; 28: 231-237.
35. Sotelo J, Torres B, Rubio-Donnadieu F et al. Praziquantel in the treatment of neurocysticercosis: long-term follow up. Neurology 1985; 35: 752-755.
36. Del Brutto OH. Albendazole therapy for subarachnoid cysticerci: clinical and neuroimaging analysis of 17 patients. J Neurol Neurosurg Psychiatr 1997; 62: 659-661.
37. Mohanty A, Venkatraman SK, Das S et al. Spinal intramedullary cysticercosis. Neurosurgery 1997; 40: 82-87.
38. Bandres J, White AC Jr, Samo T et al. Extraparenchymal neurocysticercosis: report of 5 cases and review of the literature on management. Clin Infect Dis 1992; 15: 799-822.
39. del Brutto OH. Neurocysticercosis in children: clinical and radiological analysis and prognostic factors in 54 patients. Rev Neurol 1997; 25 (147): 1681-1684.
40. Sarti E, Schantz PM, Avila G, Ambrosio J, Medina-Santillan R, Flisser A. Mass treatment against human taeniasis for the control of cysticercosis: a population-based intervention study. Trans R Soc Trop Med Hyg 2000; 94(1): 85-89.
41. Lightowlers MW. Eradication of Taerda solium cysticercosis: a role for vaccination of pigs. Int J Parasitol 1999; 29 (6): 811-817.